http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : ( Evangelia Legaki ) (검색결과 2 건)
- 무료
- 기관 내 무료
- 유료
-
Alexandra Argyrou,Evangelia Legaki,Christos Koutserimpas,Maria Gazouli,Ioannis Papaconstantinou,George Gkiokas,George Karamanolis 대한소화기 기능성질환∙운동학회 2019 Journal of Neurogastroenterology and Motility (JNM Vol.25 No.3
Background/AimsGastroesophageal reflux disease (GERD) represents a common condition having a substantial impact on the patients’ quality of life, aswell as the health system. According to many studies, the BARX1 and ADAMTS17 genes have been suggested as genetic risk loci forthe development of GERD and its complications. The purpose of this study is to investigate the potential association between GERDand BARX1 and ADAMTS17 polymorphisms. MethodsThe present is a prospective cohort study of 160 GERD patients and 180 healthy control subjects of Greek origin, examined for BARX1and ADAMTS17 polymorphisms (rs11789015 and rs4965272) and a potential correlation to GERD. ResultsThe rs11789015 AG and GG genotypes were found to be significantly associated with GERD (P = 0.032; OR, 1.65; 95% CI, 1.06-2.57 and P = 0.033; OR, 3.00; 95% CI, 1.15-7.82, respectively), as well as the G allele (P = 0.007; OR, 1.60; 95% CI, 1.14- 2.24). Concerning the rs4965272, only the GG genotype was significantly associated with GERD (P = 0.035; OR, 3.42; 95% CI, 1.06-11.05). ConclusionsThis is a study investigating the potential correlation between BARX1 and ADAMTS17 polymorphisms and the development ofGERD, showing a considerable association between both polymorphisms and the disease. This finding suggests that esophagealdifferentiation or altered regulation on microfibrils in the cell environment could be implicated as possible mechanisms in thepathogenesis of GERD.
-
( Eirini Theodoraki ),( Eleni Orfanoudaki ),( Kalliopi Foteinogiannopoulou ),( Evangelia Legaki ),( Maria Gazouli ),( Ioannis E. Koutroubakis ) 대한장연구학회 2021 Intestinal Research Vol.19 No.4
Background/Aims: The measurement of infliximab trough levels (IFX-TLs) in patients with inflammatory bowel disease (IBD) is performed to optimize treatment. However, the association between the development of adverse events (AEs) and IFX-TLs has not been sufficiently studied thus far. To investigate the possible association of IFX-TLs with AEs in Greek patients with IBD receiving maintenance treatment with IFX. Methods: A retrospective analysis of the registry data of the Gastroenterology Department of the University Hospital of Heraklion, from IBD patients with at least one available IFX-TL measurement during the years 2016 to 2017 was conducted. AEs reported 4 months before and 4 months after the measured IFX-TLs were recorded. The IFX-TLs of patients with or without AEs were compared. Results: Of a total of 83 IBD patients (61 Crohn’s disease [73%]; 52 men [63%]; mean age±standard deviation, 43.3±16.0 years), 147 measurements of IFX-TLs were available (median 4.69 μg/ mL [1.32-9.16]), and 99 AEs (67.3%, 14 severe) were registered. The median IFX-TL of patients with AEs was 5.79 μg/mL (1.36- 10.25), higher than the median IFX-TL of patients without AEs (3.40 μg/mL [1.30-5.92]), but the difference was not significant (P= 0.97). The presence of infections or dermatologic reactions was not correlated with IFX-TLs. There was no difference in the prevalence of the total AEs (66.7% vs. 73.3%, P= 0.77) or in the analysis of AEs by group between patients with IFX-TLs≥15 μg/ mL and patients with IFX-TLs<15 μg/mL. Conclusions: IFX-TLs are not significantly associated with the development of AEs in IBD patients receiving maintenance treatment with IFX. (Intest Res 2021;19:461-467)
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
